AI and robotics are revolutionizing restaurant kitchens—here’s how you can invest
Miso Robotics has already served up over 12,000 hamburgers.
- Quick service restaurants are facing growing labor, food, and real estate costs.
- Miso Robotics is working with these restaurants to lower labor costs via automation.
- Miso Robotics has already produced over 60,000 pounds of food with its revolutionary technology.
AI is being used for far more than just self-driving cars and Siri; it's playing a pivotal role in the future of the restaurant industry. Quick service restaurants (QSRs) are among the most popular eating establishments around. However, they operate on incredibly lean margins and are being confronted by rapidly increasing labor, food, and real estate costs.
Needless to say, QSRs could use a hand—and that's where AI comes into the picture.
Miso Robotics created Flippy, the world's first autonomous kitchen assistant. Designed with commercial kitchens in mind, Flippy has already cooked over 60,000 pounds of food and is in use at CaliBurger locations in Florida, as well as at stadiums servicing the Los Angeles Dodgers and Arizona Diamondbacks. White Castle, America's first fast food hamburger chain, has also partnered with Miso Robotics to develop, pilot, and undertake a beta of rollout of Miso Robotics' Flippy for White Castle's North American restaurants.
Flippy can work a grill or fryer, cooks food to perfection consistently, and can even work collaboratively with staff. In short, Flippy is a game-changer for QSRs looking to automate and cut costs.
Flippy is only the beginning for Miso Robotics, which has over a dozen patents pending in proprietary machines, learning and robotics, and control software. The company aims to make an impact in the $70.3 billion QSR market and is currently working on an overhead rail system that will cut production costs by 50 percent and leave no real estate footprint.
It's not too late to invest in Miso Robotics and the AI-powered future it's creating.
Miso Robotics has raised over $14.6 million so far, and the company's raises have been led by Wavemaker, an early-stage venture capital firm with over $335 million in assets. Wavemaker's past investments and exits include Blue Bottle Coffee, MindBody, and Clutter.
Sponsored by Miso Robotics.
Medicago is growing a SARS-CoV-2 vaccine candidate in a relative of the tobacco plant right now.
- Canadian biotech company Medicago is growing a vaccine candidate in Nicotiana benthamiana.
- An Australian relative to tobacco, plant-based vaccines could be cheaper and more reliable than current methods.
- Medicago just completed phase 3 clinical trials of an influenza vaccine, which could be a game-changer for vaccine production.
Photo: alphaspirit / Adobe Stock<p>Clark <a href="https://www.medicago.com/en/newsroom/medicago-begins-phase-i-clinical-trials-for-its-covid-19-vaccine-candidate/" target="_blank">says</a> it's important to attack the novel coronavirus from all sides.</p><p style="margin-left: 20px;">"Creating a sufficient supply of COVID-19 vaccines within the next year is a challenge which will require multiple approaches, with different technologies. Our proven plant-based technology is capable of contributing to the collective solution to this public health emergency."</p><p>Unlike many common vaccines, VLP vaccines contain no genetic material. You won't get infected by it, which is always a risk in live vaccines. </p><p>This SARS-CoV-2 vaccine is not the only project on Medicago's hands. The company <a href="https://clinicaltrials.gov/ct2/show/NCT03301051" target="_blank">just completed</a> phase 3 clinical trials on an influenza. While no plant-based vaccine has been approved for use, the company hopes to replace the more cumbersome and expensive egg-based model, or at least offset some of the costs of that model. The plant model could help researchers adapt more quickly to the ever-changing influenza strains each season. </p><p>Plants offer a wonderful alternative to the current vaccination model. Besides price, VLP vaccines scale much easier and faster. If the SARS-CoV-2 vaccine works, Medicago <a href="https://www.medicago.com/en/newsroom/medicago-begins-phase-i-clinical-trials-for-its-covid-19-vaccine-candidate/" target="_blank" rel="noopener noreferrer">believes</a> they can produce a billion doses a year, by far the most ambitious yield to date. At a time when speed, cost, and reliability are all essential factors in vaccine development, we should put tobacco to better use: healing instead of harming. </p><p>--</p><p><em>Stay in touch with Derek on <a href="http://www.twitter.com/derekberes" target="_blank">Twitter</a> and <a href="https://www.facebook.com/DerekBeresdotcom" target="_blank" rel="noopener noreferrer">Facebook</a>. His new book is</em> "<em><a href="https://www.amazon.com/gp/product/B08KRVMP2M?pf_rd_r=MDJW43337675SZ0X00FH&pf_rd_p=edaba0ee-c2fe-4124-9f5d-b31d6b1bfbee" target="_blank" rel="noopener noreferrer">Hero's Dose: The Case For Psychedelics in Ritual and Therapy</a>."</em></p>
WhiteSmoke Grammar Checker keeps your spelling and grammar issues at bay while also working as a translator.
- Grammar and spelling mistakes are rampant on the internet and on social media.
- While people are accustomed to grammar mistakes, employers take them seriously when viewing candidates.
- WhiteSmoke Grammar Checker is a powerful browser extension that keeps your spelling and grammatical issues at bay.
New cancer-scanning technology reveals a previously unknown detail of human anatomy.
- Scientists using new scanning technology and hunting for prostate tumors get a surprise.
- Behind the nasopharynx is a set of salivary glands that no one knew about.
- Finding the glands may allow for more complication-free radiation therapies.
PSMA PET/CT technology<span style="display:block;position:relative;padding-top:56.25%;" class="rm-shortcode" data-rm-shortcode-id="676e611b970c9b516cace0870447b325"><iframe type="lazy-iframe" data-runner-src="https://www.youtube.com/embed/RHAyoQF09X4?rel=0" width="100%" height="auto" frameborder="0" scrolling="no" style="position:absolute;top:0;left:0;width:100%;height:100%;"></iframe></span><p>PSMA PET/CT is a new combination of <a href="https://www.mayoclinic.org/tests-procedures/pet-scan/about/pac-20385078" target="_blank">PET scans</a> and <a href="https://www.mayoclinic.org/tests-procedures/ct-scan/about/pac-20393675" target="_blank">CT scans</a> that is believed to offer a more reliable means of locating prostate cancer metastasis. A <a href="https://www.cancer.gov/news-events/cancer-currents-blog/2020/prostate-cancer-psma-pet-ct-metastasis" target="_blank" rel="noopener noreferrer">study</a> published last spring suggests it may be the most accurate way to diagnose prostate cancer metastasis than any method previously available.</p><p>Prior to PSMA PET/CT, the primary way to look for metastatic prostate cancer was to image the body using x-ray-based CT scans and to perform bone scans, since bone is where prostate cancer often spreads. CT scans, however, often miss small tumors, and bone scans can generate false positives as a result of other damage or abnormalities that have nothing to do with prostate cancer.</p><p>PSMA PET/CT scans track the travels of an intravenously administered radioactive glucose tracer throughout the body. For hunting down prostate cancer, this tracer contains a molecule that binds to the <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1472940/" target="_blank">PSMA</a> protein that's present in large amounts in prostate tumors. The molecule is linked to a radioisotope, <a href="https://netrf.org/2018/11/13/gallium-68-scan-for-neuroendocrine-tumors/" target="_blank" rel="noopener noreferrer">gallium-68</a> (Ga-68).</p><p>In last spring's research, PSAM PET/CT was shown to be 27 percent more accurate than previous methods at finding metastases (92 percent accuracy as opposed to 65 percent). In addition, it was found to be much less likely to produce false positives, and it was particularly good at detecting tumors far removed from the prostate.</p>
A good kind of avoidance behavior<p>"Radiation therapy can damage the salivary glands," says Vogel, "which may lead to complications. Patients may have trouble eating, swallowing, or speaking, which can be a real burden."</p><p>The researchers looked back through the cases of 723 patients who had undergone radiation treatment, interested in seeing if inadvertent radiation of the tubarial glands was associated with the complications experienced by the patients. It turned out that this <em>was</em> the case: In cases where more radiation had been delivered to this area, patients did indeed report more in the way of complications of the type one would expect when salivary glands are radiated.</p><p>Now that we know the tubarial salivary glands exist, therapists can stay out of their way. Vogel says, "For most patients, it should technically be possible to avoid delivering radiation to this newly discovered location of the salivary gland system in the same way we try to spare known glands."</p><p>He's hopeful that that things may be about to get at least a bit better for cancer patients: "Our next step is to find out how we can best spare these new glands and in which patients. If we can do this, patients may experience less side effects which will benefit their overall quality of life after treatment."</p>
SMARTER FASTER trademarks owned by Freethink Media, Inc. All rights reserved.